Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 433

1.

A Pilot Randomized Cross-Over Trial to Examine the Effect of Kiwifruit on Satiety and Measures of Gastric Comfort in Healthy Adult Males.

Wallace A, Eady S, Drummond L, Hedderley D, Ansell J, Gearry R.

Nutrients. 2017 Jun 22;9(7). pii: E639. doi: 10.3390/nu9070639.

PMID:
28640214
2.

Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).

Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Hylek E, Kowey PR, Mahaffey KW, O'Brien EC, Singer DE, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

Am Heart J. 2017 Jul;189:40-47. doi: 10.1016/j.ahj.2017.03.024. Epub 2017 Apr 4.

PMID:
28625380
3.

Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation.

Black-Maier E, Kim S, Steinberg BA, Fonarow GC, Freeman JV, Kowey PR, Ansell J, Gersh BJ, Mahaffey KW, Naccarelli G, Hylek EM, Go AS, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators.

Clin Cardiol. 2017 May 19. doi: 10.1002/clc.22726. [Epub ahead of print]

4.

Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).

Steinberg BA, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

Am J Cardiol. 2017 May 15;119(10):1590-1595. doi: 10.1016/j.amjcard.2017.02.015. Epub 2017 Mar 28.

5.

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.

Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB.

JAMA Cardiol. 2017 May 1;2(5):525-534. doi: 10.1001/jamacardio.2017.0065.

PMID:
28355434
6.

Thrombophilic Evaluation in Patients with Acute Pulmonary Embolism.

Stevens SM, Ansell JE.

Semin Respir Crit Care Med. 2017 Feb;38(1):107-120. doi: 10.1055/s-0036-1597564. Epub 2017 Feb 16.

PMID:
28208204
7.

Consumption of antimicrobial manuka honey does not significantly perturb the microbiota in the hind gut of mice.

Rosendale D, Butts CA, de Guzman CE, Maddox IS, Martell S, McIntyre L, Skinner MA, Dinnan H, Ansell J.

PeerJ. 2016 Dec 20;4:e2787. doi: 10.7717/peerj.2787. eCollection 2016.

8.

Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.

Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP; ORBIT-AF Investigators and Patients.

J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604. doi: 10.1016/j.jacc.2016.09.966.

9.

Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation.

Hess PL, Kim S, Fonarow GC, Thomas L, Singer DE, Freeman JV, Gersh BJ, Ansell J, Kowey PR, Mahaffey KW, Chan PS, Steinberg BA, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Patients and Investigators.

Am J Med. 2017 Apr;130(4):449-456. doi: 10.1016/j.amjmed.2016.11.001. Epub 2016 Nov 23.

10.

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.

Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck RJ, Costin JC.

Thromb Haemost. 2017 Jan 26;117(2):238-245. doi: 10.1160/TH16-03-0224. Epub 2016 Nov 17.

PMID:
27853809
11.

How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Steinberg BA, Shrader P, Kim S, Thomas L, Fonarow GC, Ansell J, Kowey PR, Singer DE, Gersh BJ, Mahaffey KW, Peterson ED, Piccini JP; ORBIT-AF Investigators and Patients.

Am Heart J. 2016 Nov;181:145-152. doi: 10.1016/j.ahj.2016.07.026. Epub 2016 Aug 27.

12.

Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.

Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, Ansell J, Gersh BJ, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators.

Circulation. 2016 Oct 11;134(15):1122-1124. No abstract available.

PMID:
27753615
13.
14.

Reversal Agents for the Direct Oral Anticoagulants.

Ansell JE.

Hematol Oncol Clin North Am. 2016 Oct;30(5):1085-98. doi: 10.1016/j.hoc.2016.05.006. Review.

PMID:
27637309
15.

Hughes Abdominal Repair Trial (HART) - Abdominal wall closure techniques to reduce the incidence of incisional hernias: study protocol for a randomised controlled trial.

Cornish J, Harries RL, Bosanquet D, Rees B, Ansell J, Frewer N, Dhruva Rao PK, Parry C, Ellis-Owen R, Phillips SM, Morris C, Horwood J, Davies ML, Davies MM, Hargest R, Davies Z, Hilton J, Harris D, Ben-Sassi A, Rajagopal R, Hanratty D, Islam S, Watkins A, Bashir N, Jones S, Russell IR, Torkington J; HART Trial Management Group.

Trials. 2016 Sep 15;17(1):454. doi: 10.1186/s13063-016-1573-0.

16.

Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin.

Ansell JE, Laulicht BE, Bakhru SH, Hoffman M, Steiner SS, Costin JC.

Thromb Res. 2016 Oct;146:113-118. doi: 10.1016/j.thromres.2016.07.008. Epub 2016 Jul 18.

PMID:
27470323
17.

Choosing Wisely in the UK: reducing the harms of too much medicine.

Malhotra A, Maughan D, Ansell J, Lehman R, Henderson A, Gray M, Stephenson T, Bailey S.

Br J Sports Med. 2016 Jul;50(13):826-8. doi: 10.1136/bjsports-2016-h2308rep. No abstract available.

PMID:
27313236
18.

Modular emergency general surgery training: A pilot study of a novel programme.

Egan RJ, Abdelrahman T, Tate S, Ansell J, Harries R, Davies L, Clark G, Lewis WG; Wales Deanery Emergency General Surgery Working Group.

Ann R Coll Surg Engl. 2016 Sep;98(7):475-8. doi: 10.1308/rcsann.2016.0187. Epub 2016 Jun 6.

PMID:
27269241
19.

North American Thrombosis Forum, AF Action Initiative Consensus Document.

Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI.

Am J Med. 2016 May;129(5 Suppl):S1-S29. doi: 10.1016/j.amjmed.2016.02.001.

PMID:
27126598
20.

Erratum to: Guidance for the treatment of deep vein thrombosis and pulmonary embolism.

Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes RD, McBane RD, Moll S, Ansell J.

J Thromb Thrombolysis. 2016 Apr;41(3):548. doi: 10.1007/s11239-016-1345-4. No abstract available.

Supplemental Content

Loading ...
Support Center